News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanobac Life Sciences, Inc. Announces Manufacturing Agreement With Medicorp Inc. For Nanobacteria Test Kits



10/19/2005 5:11:45 PM

TAMPA, Fla., Oct. 4 /PRNewswire-FirstCall/ -- Nanobac Life Sciences, Inc. (OTCPK: NNBP) is pleased to announce the signing of a Manufacturing Agreement with Medicorp, Inc., for the production of two blood tests for the detection of Nanobacteria. Nanobac is transferring production of both the Nano-Capture ELISA assay and the Nano-Sero IgG ELISA assay from its Nanobac Oy research laboratory in Kuopio, Finland to Medicorp in preparation for FDA clinical trials and expanded distribution. Medicorp is Canada's largest, independent ISO 9001-certified manufacturer and distributor of immunodiagnostic and microbiology products.

"We are pleased to be able to work with Medicorp to scale-up production of our test kits in preparation for FDA clinical trials and for our distribution of our test kits outside the U.S., commented John Stanton, Nanobac's President and Chief Executive Officer. "This move prepares us for increased production of our test kits in an ISO-9001-certified manufacturing facility. This is a key step for the Company as we move from a research oriented company to one that rapidly develops and commercializes products."

Nanobac has already signed a distribution agreement with Oxoid Ltd. for territories in Europe, Brazil and Australia. Oxoid is one of the world's leading manufacturers and distributors of microbiological culture media and other diagnostic products. With corporate headquarters in Basingstoke, Hampshire, Oxoid Ltd is supported by a network of wholly owned sales and distribution companies in Europe, North and South America and Australia.

Nanobac recently announced that an abstract entitled "Increased serum levels of Nanobacteria antibodies are associated with high coronary calcification score" has been accepted for presentation in an oral session at the American Heart Association (AHA) Scientific Sessions 2004 conference in New Orleans, LA, Nov 7-10, 2004. The research was performed by Stephen Epstein, MD and Jianhui Zhu, PhD at the Washington Hospital Center, Washington, DC.

About Nanobacteria

Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating organism ever detected -- at 50 to 500 billionths of a meter, 1/100th the size of the smallest previously known bacteria. Nanobacteria have been implicated in a variety of human diseases associated with pathological calcification.

Nanobacteria were first discovered in 1988 by a Finnish researcher, and Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Medical microbiologist Neva Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with nanobacteria over the past 13 years has put them at the forefront of research into this medically important pathogen. Their research established that the blood-borne nanobacteria forms slow-growing calcified colonies in arteries and organs.

Nanobac has identified two biomarkers of nanobacterial infection. These tests are being developed as the NB2 test, which is composed of the nanobacteria antigen test, and the nanobacteria IgG antibody test.

About Nanobac Lifesciences

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (nanobacteria). The Company's pioneering research is establishing the pathogenic role of nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to detect and treat nanobacterial infection. The Company currently markets, through its wholly owned subsidiary, Nanobac Sciences, a patented nanobiotic regimen that it developed.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com/.

About Medicorp

MEDICORP is Canada's largest, independent ISO 9001-certified manufacturer and distributor of immunodiagnostic and microbiology products. MEDICORP manufactures and markets state-of-the-art immunoassay products, Monoclonal Antibodies for Neuroscience and a broad line of Polyclonal Antibodies to Peptide and Steroid hormones in Canada and through distributors in Europe and Asia. MEDICORP's Free PSA [fPSA] assay has revolutionized the differential diagnosis of prostate cancer.

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.

For more information contact: John Stanton or Alex Edwards Nanobac Life Sciences, Inc. 813-264-2241 Media: Cynthia Isaac, PhD The Ruth Group 646-536-7028 cisaac@theruthgroup.com

Nanobac Life Sciences, Inc.

CONTACT: Alex Edwards, President, Chief Executive Officer, Nanobac LifeSciences, Inc., +1-813-264-2241; or Media: Cynthia Isaac, PhD, The Ruth Group,+1-646-536-7028, cisaac@theruthgroup.com, for Nanobac Life Sciences


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES